Literature DB >> 70437

Human lung tissue and anaphylaxis. I. The role of cyclic GMP as a modulator of the immunologically induced secretory process.

M Kaliner.   

Abstract

A close relationship between increased concentrations of cyclic GMP in human lung tissue and the capacity for acetylcholine to enhance the immunologic secretion of histamine and SRS-A has been found. Acetylcholine (10(-7) to 10(-11) M) produced parallel increases in both cyclic GMP and the immunologic release of mediators; the muscarinic blocking agent atropine prevented both responses. The increase in cyclic GMP in human lung after acetylcholine stimulation was apparent within 30 sec, peaked by 120 sec, and abruptly returned to control levels thereafter. The ability of acetylcholine to enhance the antigen-stimulated secretion of mediators followed the same time-course. PGF2alpha (3.3 X 10(-4) M to 3.3 X 10(-7) M) increased the cyclic GMP content of human lung tissue in a dose-related fashion. Pretreatment of IgE-sensitized lung tissue with acetylsalicylic acid (10 microgram/ml) had no effect on baseline cyclic nucleotide levels, the capacity for antigen to induce mediator release, or the increase in cyclic GMP and facilitation of the immunologic release of mediators produced by acetylcholine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70437     DOI: 10.1016/0091-6749(77)90125-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  Sympathetic modulation of biochemical and physiological response to immune degranulation in canine bronchial airways in vivo.

Authors:  E R Garrity; N P Stimler; N M Munoz; J Tallet; A C David; A R Leff
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

2.  Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content.

Authors:  M M Little; D R Wood; T B Casale
Journal:  Agents Actions       Date:  1989-08

3.  Immunologic and neuropharmacologic stimulation of mucous glycoprotein release from human airways in vitro.

Authors:  J H Shelhamer; Z Marom; M Kaliner
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

4.  Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.

Authors:  N Frossard; Y Landry; G Pauli; M Ruckstuhl
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

5.  Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness.

Authors:  T B Casale; D Wood; H B Richerson; S Trapp; W J Metzger; D Zavala; G W Hunninghake
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

Review 6.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

7.  The effects of the immunologic release of histamine upon human lung cyclic nucleotide levels and prostaglandin generation.

Authors:  L F Platshon; M Kaliner
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

8.  Preparation of a human lung purified plasma membrane fraction: confirmation by enzyme markers, electron microscopy, and histamine H1 receptor binding.

Authors:  T B Casale; M Friedman; N Parada; J Plekes; M Kaliner
Journal:  J Membr Biol       Date:  1984       Impact factor: 1.843

9.  Modulation of human natural killer cell activity by pharmacological mediators.

Authors:  T J Hall; S H Chen; J Brostoff; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

10.  Time-dependent effect of prostaglandin E2 inhalation on airway responses to bronchoconstrictor agents in normal subjects.

Authors:  E H Walters; C Bevan; R W Parrish; B H Davies; A P Smith
Journal:  Thorax       Date:  1982-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.